These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091 [TBL] [Abstract][Full Text] [Related]
5. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341 [TBL] [Abstract][Full Text] [Related]
6. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Haugaard SB; Andersen O; Vølund A; Hansen BR; Iversen J; Andersen UB; Nielsen JO; Madsbad S Clin Endocrinol (Oxf); 2005 Mar; 62(3):354-61. PubMed ID: 15730419 [TBL] [Abstract][Full Text] [Related]
7. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441 [TBL] [Abstract][Full Text] [Related]
8. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675 [TBL] [Abstract][Full Text] [Related]
9. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768 [TBL] [Abstract][Full Text] [Related]
10. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Toft-Nielsen M; Madsbad S; Holst JJ Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105 [TBL] [Abstract][Full Text] [Related]
11. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937 [TBL] [Abstract][Full Text] [Related]
12. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468 [TBL] [Abstract][Full Text] [Related]
13. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Ranganath LR; Beety JM; Morgan LM Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081 [TBL] [Abstract][Full Text] [Related]
15. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226 [TBL] [Abstract][Full Text] [Related]
16. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Muscelli E; Mari A; Natali A; Astiarraga BD; Camastra S; Frascerra S; Holst JJ; Ferrannini E Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1144-50. PubMed ID: 16478775 [TBL] [Abstract][Full Text] [Related]
17. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Pacini G; Thomaseth K; Ahrén B Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002 [TBL] [Abstract][Full Text] [Related]
18. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Svendsen PF; Nilas L; Madsbad S; Holst JJ Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579 [TBL] [Abstract][Full Text] [Related]
19. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044 [TBL] [Abstract][Full Text] [Related]
20. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]